AKT Kinase Inhibitor is an Akt inhibitor with antitumor activity that selectively inhibits cell proliferation in a dose-dependent manner.

AKT Kinase Inhibitor HCl is an Akt inhibitor with antitumor activity.

AKT-I-1 is a selective and reversible inhibitor of Akt1.

Akt-I-1,2 is a selective inhibitor of Akt1 and Akt2.

PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor.PI3K/Akt/mTOR-IN-2 has anticancer effects and is selective for MDA-MB-231 cells with an IC50 of 2.29 μM.PI3K/Akt/mTOR-IN-2 exhibits anticancer activity and induces cycle arrest and apoptosis in cancer cells. PI3K/Akt/mTOR-IN-2 has anticancer activity and can induce cycle arrest and apoptosis in cancer cells.

Akt3 degrader 1 is a specific Akt3 degrader with anticancer and antiproliferative activity that inhibits tumor growth in mice.Akt3 degrader 1 is used in the study of non-small cell lung cancer and pancreatic cancer.

AKT inhibitor VIII (AKTi-1/2) is a highly specific Akt1/2 inhibitor (IC50: 58/210 nM). The selectivity for Akt1 is higher about 36-fold than Akt3.

Akt1-IN-1 is a potent and selective inhibitor of Akt1, demonstrating an IC50 of 18.79 nM in MIA PaCa-2 cells, indicating its high efficacy in inhibiting this specific kinase. Notably, it shows no significant teratogenicity, hepatotoxicity, or cardiotoxicity (No Observed Adverse Effect Level > 100 µM), making it a viable candidate for anticancer research.

PI3K/AKT-IN-2, a dual inhibitor of PI3K and AKT, prevents the epithelial-mesenchymal transition (EMT) and promotes apoptosis. Additionally, it impedes tubulin polymerization.

PI3K/Akt-IN-C89 is a novel Inhibitor of the PI3K-Akt Pathway, Inducing Autophagy of Female Germline Stem Cells.

AKT-IN-9 is a potent inhibitor of AKT. AKT-IN-9 has potential for breast and prostate cancer research.

AKT-IN-13 (compound 4b) is a potent inhibitor of Akt, acting on Akt1 (IC50: 1.6 nM), Akt2 (IC50: 2.4 nM) and Akt3 (IC50: 0.3 nM). AKT-IN-13 can be used in anticancer research.

AKT-IN-7 (compound 1-P1) is a potent inhibitor of AKT. AKT-IN-7 has potential for cancer research.

(E)-Akt inhibitor-IV ((E)-AKTIV)  ((E)-AKTIV) is an inhibitor of PI3K-Akt.

AKT-IN-1 (AZD-26) is an allosteric AKT inhibitor (IC50: 1.04 μM).

Akt Antibody #9272R is a useful organic compound for research related to life sciences and the catalog number is T64603.

Akt/NF-κB/MAPK-IN-1 (compound 2m) serves as a potent, orally active inhibitor targeting NO with an IC50 of 7.70 μM and demonstrates low toxicity. This compound exerts anti-inflammatory effects by impeding the Akt/NF-κB and MAPK signaling pathways [1].

Akt Inhibitor X is a cell-permeable and reversible inhibitor of Akt phosphorylation.

PI3K/Akt/CREB Activator 1 is a potent, orally active compound that acts as an activator for the PI3K/Akt/CREB pathway. It enhances neuronal proliferation, induces differentiation of Neuro-2a cells into neuron-like morphology, and accelerates axon-dendrite polarization in primary hippocampal neurons by upregulating brain-derived neurotrophic factor. This compound is utilized in vascular dementia (VaD) research.

AKT Kinase Inhibitor hydrochloride is an Akt kinase inhibitor with anti-tumor activity .

Akt/SKG Substrate Peptide TFA is a synthetic peptide designed as a substrate specifically for Akt/PKB and is not phosphorylated by p70S6K or MAPK1 [1].

AKT-IN-8 is a potent inhibitor of AKT, acting on AKT1 (IC50: 4.46 nM), AKT2 (IC50: 2.44 nM) and AKT3 (IC50: 9.47 nM).

AKT-IN-5 (Example 8) is a chemical compound known as an Akt inhibitor, specifically targeting Akt1 and Akt2. Its potency is reflected in IC50 values of 450 nM and 400 nM for Akt1 and Akt2, respectively [1].

Akt/ROCK-IN-1 (B12) is a dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively. It possesses antitumor efficacy against neuroblastoma [1].

Akt1&PKA-IN-2 ((R)-29), a compound with specificity towards PKB/AKT and notable selectivity for cyclin-dependent kinase 2 (CDK2), effectively inhibits AKT1, PKAa, and CDK2a with IC50 values of 0.007 µM, 0.01 µM, and 0.69 µM, respectively.

AKT-IN-10 is a potent AKT inhibitor that has shown research potential in breast and prostate cancers. Among them is protein kinase B (PKB, also known as AKT), which is central to PI3K/AKT/mTOR signaling in cells and whose function is important for cell growth, survival, differentiation and metabolism.

AKT-IN-11 is one of the most potent antibacterial agents against human hepatocellular carcinoma Bel-7402 cell line (IC50: 1.15 μM).

AKT-IN-6 (INCB-047775) has an inhibitory effect on ATK. Akt is an important component of cellular signaling for growth factors, cytokines, and other cell stimuli. Abnormal Akt activation has been associated with the development of type 2 diabetes mellitus and cancer.

Phospho-Akt (Ser473) Antibody #9271R is a useful organic compound for research related to life sciences and the catalog number is T64583.

Tubulin/AKT1-IN-1 (Compound D1-1) serves as an inhibitor of both tubulin polymerization and AKT pathway activation, effectively suppressing proliferation and metastasis of H1975 cells while modestly inducing apoptosis. This compound is utilized in the study of non-small-cell lung cancer (NSCLC) [1].

AKT-IN-18, an Akt inhibitor, demonstrates an IC50 value of 69.45 μM in A549 cells, effectively impeding Akt activity. It promotes apoptosis and is suitable for use in non-small cell lung cancer research [1].

substrate for Akt/PKB

PI3K/AKT-IN-1 is a potent, dual PI3K/AKT inhibitor that acts on PI3Kγ (IC50: 6.99 μM), PI3Kδ (IC50: 4.01 μM) and AKT (IC50: 3.36 μM). PI3K/AKT-IN-1 induces caspase 3-dependent apoptosis by inhibiting the PI3K/AKT pathway. caspase 3-dependent apoptosis and exhibited anticancer effects.

AKT-IN-2 is a selective, and orally bioavailable AKT inhibitor (IC50: 5 nM for AKT1).

Akt1&PKA-IN-1 is a potent dual inhibitor targeting Akt and PKA, exhibiting IC50 values of 0.11 μM for Akt, 0.03 μM for PKAα, and 9.8 μM for CDK2. Notably, it demonstrates selectivity for cyclin-dependent kinase 2 (CDK2).

APN/AKT-IN-1 is a potent dual inhibitor of aminopeptidase N (APN) and protein kinase B (AKT), exhibiting IC50 values of 0.21 μM and 0.27 μM for APN and AKT inhibition, respectively. This compound effectively suppresses the phosphorylation of glycogen synthase kinase 3 beta (GSK3β), which serves as an intracellular substrate of AKT [1].

AKT-IN-3 is a potent, orally active low hERG blocking Akt inhibitor (IC50: 1.4 nM, 1.2 nM, and 1.7 nM for Akt1, Akt2, and Akt3). AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1

Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signalling pathways.Akt/NF-κB/JNK-IN-1 exhibits an inhibitory effect on nitric oxide production (IC50: 3.15 μM) and shows anti-inflammatory effects.

PF-AKT400 (AKT protein kinase inhibitor) is a broadly selective and ATP-competitive inhibitor of Akt.

PI3K/Akt/mTOR-IN-3 is a potent inhibitor of PI3K/Akt/mTOR. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 cells (IC50: 0.77 μM), HeLa cells (IC50: 1.23 μM) and HepG2 cells (IC50: 4.57 μM). PI3K/Akt/mTOR-IN-3 inhibited the migration of MCF-7 and HeLa cells at a concentration of 4 μM. PI3K/Akt/mTOR-IN-3 blocked the cell cycle in S phase and induced apoptosis.

SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IκBα kinase activation.

Miransertib (ARQ-092) is an orally bioavailable, selective, and potent allosteric Akt inhibitor.

Ipatasertib (GDC-0068) (GDC-0068), a highly specific pan-Akt inhibitor, targets Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, respectively.

MK-2206 dihydrochloride (MK-2206 2HCl) is a variant Akt inhibitor that inhibits Akt1, Akt2, and Akt3 (IC50=8/12/65 nM) with orally active, highly potent and selective potency. MK-2206 dihydrochloride exhibits antitumor activity.

TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM).

Alpelisib (BYL-719) is a PI3Kα inhibitor (IC50=5 nM) with selective, potent, and oral activity. Alpelisib inhibits PI3Kβ/γ/δ with low activity (IC50=250/290/1200 nM). Alpelisib has antitumor activity and is targeted to PIK3CA mutant tumors.

Uprosertib (GSK2141795) (GSK2141795) is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with IC50 of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.

Capivasertib (AZD5363) is a broad-spectrum AKT inhibitor with inhibitory activity against Akt1, Akt2, and Akt3 (IC50=3/7/7 nM) with oral activity. Capivasertib has antitumor activity for the treatment of breast cancer.

Butein (2’,3,4,4’-tetrahydroxy Chalcone), a plant polyphenol, is isolated from Rhus verniciflua. It can inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, and also can inhibit EGFR.

Deferoxamine Mesylate (DFOM) is an iron chelator and iron death inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.